ACOG Develops Consensus on Medical Menstrual Suppression
Guidance emphasizes role of hormonal therapy and should be accompanied by counseling, including discussions of effectiveness of therapy
Menorrhagia
FDA to Review Data on Long-Term Use of Myfembree for Uterine Fibroids
The study enrolled women who completed the 24-week LIBERTY 1 and 2 studies and the 28-week open-label extension studies, and who met the definition of a responder.
Linzagolix Under Review for Treatment of Uterine Fibroids
Linzagolix is a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
Linzagolix NDA Submitted for Uterine Fibroid Treatment
The NDA submission is supported by data from the phase 3 PRIMROSE 1 and PRIMROSE 2 studies, along with data from the 76-week post-treatment follow-up study.
Dexamethasone Studied for Treatment of Heavy Menstrual Bleeding
Results of dose-finding study suggest dexamethasone is safe for use at a dosage of 1.8 mg daily for five days per menstrual cycle
Myfembree Now Available for Heavy Menstrual Bleeding With Uterine Fibroids
Myfembree consists of relugolix, a gonadotropin-releasing hormone receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin.
Myfembree Approved for Heavy Menstrual Bleeding With Uterine Fibroids
Myfembree is a combination of relugolix, a gonadotropin-releasing hormone receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin.
Consistent Benefits Seen With Linzagolix in Uterine Fibroids Trial
At 76 weeks, results showed that off-treatment pain scores remained lower than baseline across all linzagolix treatment arms.
Relugolix Combo Therapy Beneficial for Fibroid-Related Menorrhagia
Significantly more women had reduced menstrual bleeding with once-daily relugolix combination therapy versus placebo
FDA to Review Relugolix Combination Therapy for Uterine Fibroids
The NDA submission is supported by results from the phase 3 LIBERTY program.
